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This article proposes using genomic information to help tailor the output of a drug interaction program for a patient. This paper
focuses on a particular CYP450 enzyme to illustrate adding genomic information to an existing drug interaction database. The data
are formatted as an Extensible Markup Language (XML) document. The additional interaction information based on genomics for
a patient is added to an XML document using XML tags. The suggestion is to combine speciﬁcs about a patient’s genome with
genomic information in the drug interactions database to increase the accuracy and details of a drug interaction program.
 2004 Elsevier Inc. All rights reserved.
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XML1. Introduction and overview
Adverse drug interactions present a problem for
doctors prescribing medication. This problem is be-
coming more diﬃcult because the volume of docu-
mented interactions is increasing. The interactions table
in The Medical Letter Handbook of Adverse Drug In-
teractions increased from 294 pages in the 1997 edition
[1] to 503 pages in the 2003 edition [2]. The ability of
informatics to help warn clinicians of adverse drug in-
teractions was mentioned as part of the grave problem
of adverse drug events presented in a study published in
JAMA. This study suggested a 6.5 rate of adverse drug
events per 100 nonobstetrical hospital admissions [3].
The study concluded that adverse drug events were
common and often preventable. Another study of hos-
pital medical errors, To Err is Human, stated that
medication errors now occur frequently in hospitals, yet
many hospitals are not making use of known systems to
improve safety [4]. The cost of these adverse drug events
from errors, that are preventable, is probably in the
billions of dollars. Adverse drug interactions are part ofE-mail address: gardner@rockefeller.edu.
1532-0464/$ - see front matter  2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2004.05.001the overall problem of adverse drug events. The study
mentioned that the use of informatics was a way to help
combat the problem of medication errors.
Currently there are many drug interaction programs
and handbooks to help warn clinicians of adverse drug
interactions. Three well known sources for drug inter-
action information include Facts and Comparisons [5]
whose product Drug Interaction Facts, features drug–
drug and drug–food interaction information in a quick
electronic format, First Data Bank whose product
Evaluations of Drug Interactions (EDI) is a compre-
hensive source of drug–drug interaction information [6],
and The Medical Letter database of adverse drug in-
teractions [7]. This paper uses as its example and source
of drug interaction information The Medical Letter
database because it is easy to manipulate and readily
available to the author.
This database lists interactions under groupings of
drug–drug pairs. It is available as a printed book, or in
electronic form as a set of data ﬁles accessible through
PDA, personal computer, and web-based programs. The
programs read a list of drugs, normally a patient drug
list, then search the database for adverse drug interac-
tions. The output is not tailored to the patient, except by
the program’s patient drug list.
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Adverse drug interactions may be more accurately
reported if contextual information other than simply a
medication list is available about a patient. Such
contextual information includes the patient’s basic
proﬁle, medical condition, and genetic makeup. This
paper addresses the relationship between drug inter-
actions and genetic information about the patient. By
tailoring a patient’s adverse drug interaction report to
the patient’s known genetic makeup, a more accurate
picture of possible interactions between a patient’s
medications may be provided to health care profes-
sionals.
This paper exempliﬁes the inﬂuence of genetic in-
formation on drug interactions, and discusses the way
in which the dependency of drug interactions on ge-
netic variations can be modeled in an XML data
document.
This paper proposes reducing drug interactions by
tailoring the presentation of drug interaction informa-
tion based on genetic diﬀerences that aﬀect drug me-
tabolism and interactions. According to a physician, a
clinical imperative for Pharmacogenetics is to tailor a
patient’s treatment by individual characteristics such as
genetic makeup. The physician states the evidence of
tailoring the treatment to the patient is meager in
pharmacology [8]. This paper suggests that incorporat-
ing the knowledge of the patient’s genetic diﬀerences
into an adverse drug interaction database would be a
signiﬁcant step toward providing personalized drug in-
teraction results that would improve the adverse drug
interaction reporting. The drug interaction data would
be presented in a tagged XML document and would be
extended with another XML document containing ge-
netic data.3. Genetic eﬀects on drug interactions
The cytochrome P450 (or CYP450) enzyme system is
a major metabolic pathway for drugs and other sub-
stances. Knowledge of the substrates, inhibitors, and
inducers of the CYP450 system and how one drug aﬀects
another drug’s performance via this system can assist in
the prediction of serious adverse drug interactions [9]. A
few of the enzymes in this system participate in the
metabolism of most drugs [10].
These genetic variations can contribute to individ-
ual variability in drug response and safety, including
drug interactions. There are 480 references to the
CYP450 enzyme in the database of 2822 adverse ef-
fects [11]. The CYP450 enzymes take part in the
metabolism of many drugs. Many drug–drug inter-
actions can be explained by competition for these
enzymes or eﬀects on these enzymes. The eﬀects on aCYP450 enzyme may be to inhibit the enzyme, that
is, reduce its activity, or to induce the enzyme, that
is, increase its activity [12]. For example, quinidine
inhibits the CYP2D6 isoenzyme, that is, reduces its
activity. CYP2D6 metabolizes b-blockers, such as
metoprolol [13]. Adding metoprolol to a patient’s
regimen that includes quinidine can result in a drug
interaction, in particular, metoprolol toxicity due to
this decreased metabolic activity [14].
There are genetic diﬀerences other than those asso-
ciated with the CYP450 family that aﬀect drug interac-
tions. For example, there are genetic diﬀerences with the
P-glycoprotein transporter that have been shown to af-
fect drug interactions in diﬀerent individuals [15]. There
are also other enzymes that aﬀect drug metabolism, such
as those involved in glucuronidation, that vary in
function due to genetic variation and may have an aﬀect
on interactions.
This paper focuses on a particular CYP450 enzyme
to illustrate its proposal to add genomic information
to the database. It focuses on an enzyme in the CYP2C
Isoenzyme subfamily. This subfamily metabolizes
several drugs that are involved in signiﬁcant drug
interactions [16].4. CYP2C19 eﬀect on interactions
CYP2C19 is a genetically determined enzyme, S-me-
phenytoin 40-hydroxylase. Its phenotypes include poor
metabolism and excessive metabolism. It metabolizes
drugs such as diazepam. When another drug is a sub-
strate for this enzyme, or an inhibitor, or inducer of this
enzyme, an interaction may occur [17]. For example,
ﬂuvoxamine is an inhibitor of CYP2C19 that reduces its
activity, and aﬀects the disposition of diazepam, which is
metabolized by CYP2C19, causing a drug interaction.
There are various genotypes of CYP2C19. These ge-
netic variations determine whether CYP2C19 acts as a
poor metabolizer or an excessive metabolizer [17]. These
diﬀerent phenotypes can aﬀect a drug’s metabolism or
interactions between drugs that aﬀect CYP2C19 or that
are aﬀected by CYP2C19.
A table of the various genotypes of CYP2C19 and
resulting enzyme activity is available at http://
www.imm.ki.se/CYPalleles. The detection of the muta-
tions causing allele variants can predict the phenotype.5. Examples of interactions aﬀected by CYP2C19 geno-
types
There are several examples of interactions involving
the CYP2C19 enzyme mentioned in The Medical Letter
database of adverse drug interactions. Two examples
follow.
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omeprazole
From the drug interaction program:
DRUG LIST IS
MAO inhibitors (Monoamine oxidase inhibitors)
Omeprazole
INTERACTION FOR:
MAO inhibitors (Monoamine oxidase inhibitors)
Omeprazole
Eﬀect 1:
Possible moclobemide toxicity (decreased metabo-
lism; CYP2C19)
Reference citation:
K-S Yu et al., Eﬀect of omeprazole on the pharmaco-
kinetics of moclobemide according to the genetic
polymorphism of CYP2C19. Clin Pharmacol Ther,
69:266, 2001
Comment/Recommendation:
Based on study in healthy subjects; monitor clinical
status
—————————
Based on issue 21—February 2004 [18]
In this case, a study showed that the eﬀect of ome-
prazole on moclobemide was diﬀerent with regard to the
genetic polymorphism of CYP2C19. Patients with ge-
notypes that indicated extensive metabolism greatly in-
hibited the elimination of moclobemide, but this was not
the case in patients whose genotypes indicated poor
metabolizers [19]. In this study, the interaction between
the two drugs is signiﬁcantly diﬀerent depending on the
genotype of CYP2C19.5.2. Example 2: Lansoprazole with Theophyllines
DRUG LIST IS
Lansoprazole
Theophyllines
INTERACTION FOR:
Lansoprazole
Theophyllines
Eﬀect 1:
Possible decreased theophylline eﬀect in some pa-
tients (increased metabolism)
Reference citation:
T Kokufu et al., Eﬀects of lansoprazole on pharma-
cokinetics and metabolism of theophylline. Eur J Clin
Pharmacol, 48:391, 1995;
J-W Ko et al., Theophylline pharmacokinetics are
not altered by lansoprazole in CYP2C19 poor metab-
olizers. Clin Pharmacol Ther, 65:606, 1999;K Dilger et al., Lack of drug interaction between
omeprazole, lansoprazole, and theophylline. Br J Clin
Pharmacol, 48:438, 1999
Comment/Recommendation:
Eﬀect small; clinical signiﬁcance probably minimal;
no interaction found in healthy subjects given intra-
venous theophylline; no interaction found in healthy
subjects given oral theophylline
————————
Based on issue 21—February 2004 [18]
In this interaction, between lansoprazole and theo-
phyllines, a study showed that groups with diﬀerent
CYP2C19 genotypes for poor metabolizers or extensive
metabolizers showed signiﬁcant diﬀerences in the phar-
macokinetics of lansoprazole. However, the usual doses
of lansoprazole had no clinically signiﬁcant inﬂuence on
theophylline clearance. That is, the genotype for poor
metabolizers had no clinically signiﬁcant interaction
compared to the genotype for extensive metabolizers
[20].
We can see from these examples that the diﬀerent ge-
notypes for CYP2C19 can result in signiﬁcant diﬀerences
in metabolism. In one, there was a signiﬁcant diﬀerence in
the interaction depending on genotypes. In the other,
there was not a clinically signiﬁcant diﬀerence in the in-
teraction because diﬀerent metabolic pathways compen-
sated for the CYP3C19 poor metabolizer variant.6. Modifying the database of adverse drug interactions
with genotype information
This section will discuss the format of the adverse
drug interaction data, XML technology and why XML
was chosen to represent the drug interactions data,
adding additional information for drug interactions
based on genetic diﬀerences, gathering genomic data for
patients, and oﬀer a hypothetical example of using ge-
nomic information in a drug interaction program.
6.1. Description of the adverse drug interactions database
The available drug interaction source database,
available to researchers and others, is easily modiﬁed to
other formats. The source format for Example 1 above
is
drug1:Monoamine oxidase inhibitors
drug2:Omeprazole
effect:
Possible moclobemide toxicity (de-
creased metabolism; CYP2C19)
references:
K-S Yu et al., Effect of omeprazole on the
pharmacokinetics of moclobemide accord-
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P2C19.Clin Pharmacol Ther, 69:266, 2001
comment:
Based on study in healthy subjects; moni-
tor clinical status [11]
Using various text tools, such as those in the
Perl language, this source was changed to XML
format.
If the document drug interaction information is up-
loaded to a database system, it should be noted that the
concatenation of drug1 and drug2 form a unique iden-
tiﬁer and there is always a reference and comment sec-
tion for each eﬀect.6.2. What is XML and why use it to represent our data?
One deﬁnition of XML is that it is a family of tech-
nologies that can do everything from formatting docu-
ments to ﬁltering data [21]. XML is a syntax and
grammatical system for constructing markup languages.
The Medical Letter has a research XML document for
describing drug interactions for possible use in an
Electronic Medical Record (EMR). In the adverse drug
interaction XML document tags are deﬁned following
the XML syntax rules.
An XML representation for the Monoamine oxidase
inhibitors and Omeprazole presented above follows.
This is one of many interactions enclosed in <interac-
tion></interaction> tags. This XML document was
created from the source data above by using various
text-processing tools such as a stream editor or Perl.
Since the source document was well delimited with
keywords such as ‘‘drug1:’’, ‘‘drug2:’’, ‘‘eﬀect:’’, ‘‘refer-
ences:’’, ‘‘comment:’’, and parentheses to mark mecha-
nism of interactions, the process of translating the
source document to the XML document was fairly
straight forward.
<xml version¼ ‘‘1.0’’?>
<Medical_Letter_Drug_Interactions>
<interaction>
<inter_drug>Monoamine oxidase inhibitors
</inter_drug>
<inter_drug>Omeprazole</inter_drug>
<adverse_eﬀect>
Possible moclobemide toxicity
<mechanism_of_interaction> decreased metabo-
lism; CYP2C19</mechanism_of_interaction>
</adverse_eﬀect>
<references>
<citation>K-S Yu et al., Eﬀect of omeprazole on
the pharmacokinetics of moclobemide according
to the genetic polymorphism of CYP2C19. Clin
Pharmacol Ther, 69:266, 2001</citation>
</references><comment> Based on study in healthy subjects;
monitor clinical status</comment>
</interaction>
</Medical_Letter_Drug_Interactions>6.3. Adding genomic data for the drug interactions data
Although this paper’s emphasis is the eﬀects of
CYP2C19 variations on drug interactions, other factors
can aﬀect drug interactions. A patient’s age, nutrition,
environment such as pollution, disease state, and infec-
tious diseases aﬀect a patient’s response to drugs and
can have an aﬀect on drug interactions [22]. Therefore,
the proposal to add genotype information to an XML
document will be to add it to part of a general section of
patient speciﬁc information. The XML heading for this
will be <Patient_Variables>, which will contain the
genotype information.
The representation of the CYP genotype information
can follow the current nomenclature. In CYP2C19 the
‘2’ speciﬁes enzyme family (there are 14 known families
in humans), the ‘C’ designates the sub-family (42 known
in humans), and the ‘19’ indicates the speciﬁc enzyme.
Pairs of asterisks with numbers can follow the speciﬁc
enzyme as in CYP2C19*1/*2. The *1/*2 designates the
‘‘allele pattern.’’ We can have two numbers here since
we have two copies of every gene. The number 1, is the
most common form of the gene, and a number 2 or
greater indicates a variant [22].
Using this nomenclature in our XML document
we can deﬁne an XML tag for all patient speciﬁc
information under <Patient_Variables>. Within the
<Patient_Variables> section we can have the tag
<gene> with an allele attribute. This allele attribute
would have the allele information, e.g., <gene al-
lele¼ ‘‘CYP2C19*1/*1’’>. Under <gene> we could
have a <drug_interactions> tag that would contain
speciﬁc information relating the allele for <gene> to the
drug interaction.
The source of the drug interaction with genomics
information would be a content editor who would write
and input the information after a review of the scientiﬁc
literature. This would be a signiﬁcant task.
6.4. Getting the genotype or phenotype information for a
patient data record
Another step in this process would be to get the ge-
notype information for the patient and relate it to our
data of known genomic eﬀects on drug interactions
mentioned in the previous section. It is possible to per-
form tests to determine genotype or phenotype behavior
for the CYP enzymes, including CYP2C19. For exam-
ple, one way to determine genotypes for CYP2C19 is to
use polymerase chain reaction analysis. By searching for
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metabolism’’ a determination can be made whether the
patient is a poor metabolizer or excessive metabolizer
[19]. In the future, mapping a patient’s genome may
someday be both possible [23] and aﬀordable [24] al-
though some patients may be wary to get their genome
and give it to a health care provider [25]. Nevertheless,
with our continued understanding of genetic polymor-
phism and development of gene chip technology, it is
quite feasible for individuals to be genotyped with re-
spect to the enzymes of interest [26]. A major pharma-
ceutical company has already announced a gene test to
predict how a person will react to many prescribed
medicines. The test runs on a gene chip capable of de-
tecting many gene variations [27,28]. Some have even
suggested that patients could carry a ‘‘smart card’’ of
patient medical information containing the enzyme ge-
netic information [26]. So, in the future, getting the
patient genomic data for use in an electronic medical
record should be possible.6.5. Relating the patient data genomic information to the
drug interaction genomic information
A system that would make use of the genomic in-
formation for a patient’s drug interactions would have
to associate the genomic data for the patient (Section
6.4), the data for a particular drug interaction (Section
6.3), and the patient’s drug list. One could complete this
by transferring the information to a database system or
using XML parsers.6.6. A hypothetical example for adding genomic informa-
tion
The interaction between Lansoprazole and Tacroli-
mus as an XML document is:
<?xml version¼ ‘‘1.0’’ ?>
<Medical_Letter_Drug_Interactions>
<interaction>
<inter_drug>Lansoprazole</inter_drug>
<inter_drug>Tacrolimus</inter_drug>
<adverse_eﬀect>
Possible increased tacrolimus toxicity
<mechanism_of_interaction>mechanism not
established</mechanism_of_interaction>
</adverse_eﬀect>
<references>
<citation>MHomma et al., Eﬀects of lansop-
razole and rabeprazole on tacrolimus blood
concentration: case of a renal transplant re-
cipient with CYP2C19 gene mutation.
Transplantation, 73:303, 2002</citation>
</references><comment>Single case report (2002) in patient
with reduced CYP2C19 activity; causal rela-
tionship not established; monitor tacrolimus
concentrations and clinical status; neither rab-
eprazole nor famotidine appeared to aﬀect ta-
crolimus</comment>
</interaction>
</Medical_Letter_Drug_Interactions> [11]
The only case report for this interaction occurred
with a patient who had a CYP2C19 gene mutation. The
clinicians noticed a signiﬁcantly high level of tacrolimus
and suspected an interaction between lansoprazole and
tacrolimus. The clinicians used a polymerase chain re-
action analysis test to determine that the patient had
heterozygous mutation at exon 5 of CYP2C19. The
nomenclature for this is CYP2C19*1/*2. The *1 repre-
sents the common allele, the *2 represents the mutation.
With the hypothesis that the mutant allele is more likely
to cause an interaction than the non-mutant allele we
could add XML code to the database. Since this infor-
mation is meant to tailor the presentation of the inter-
actions for a particular patient, we could include our
information within <Patient_Variables> tags. Since we
want to include genomic information, we introduce a
<gene> tag with an attribute indicating the genetic al-
lele. Then we introduce an interaction tag, signifying
that this gene could inﬂuence the interaction between the
drugs mentioned signiﬁed with attribute tags drug1 and
drug2. The document data for this interaction could be
‘‘increased interaction risk, see comment and refer-
ences,’’ referring to the comment in the program’s or
handbook’s interaction regarding the case report from
2002.
<?xml version¼ ‘‘1.0’’?>
<Patient_Variables xmlns:xsi¼ ‘‘http://www.w3.org/
2000/10/XMLSchema-instance’’ xsi:noNamespace-
SchemaLocation¼ ‘‘C:nDocuments and Settingsn
Don GardnernDesktopnpaperngene_emr.xsd’’>
<gene allele¼ ‘‘CYP2C19*1/*2’’>
<drug_interaction>
<inter_drug>Lansoprazole</inter_drug>
<inter_drug>Tacrolimus</inter_drug>
<eﬀect_modiﬁcation>
increased interaction risk, see interactions
comment and references
</eﬀect_modiﬁcation>
</drug_interaction>
</gene>
<gene allele¼ ‘‘CYP2C19*1/*1’’>
<drug_interaction>
<inter_drug>Lansoprazole</inter_drug>
<inter_drug>Tacrolimus</inter_drug>
<eﬀect_modiﬁcation>
interaction not seen for this allele, see com-
ment and references
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</drug_interaction>
</gene>
</Patient_Variables>
Since this interaction has not been documented here
without the mutation, after further study it may be
determined that the interaction does not occur unless
there is a mutation. In that case, we could add
more information nested under <Patient_Variables> as
shown above in the document under <gene allele¼
CYP2C19*1/*1>.
An advantage to XML is that schema can be written
to describe and validate an XML document. A schema
that validated for the above XML document is:
<?xml version¼ ‘‘1.0’’?>
< !– edited with XMLSPY v2004 rel. 3 U (http://
www.xmlspy.com) by Don Gardner (The Medical
Letter) –>
<xsd:schema xmlns:xsd¼ ‘‘http://www.w3.org/2001/
XMLSchema’’>
<xsd:element name¼ ‘‘Patient_Variables’’ type-
¼ ‘‘PVtype’’/>
<xsd:complexType name¼ ‘‘PVtype’’>
<xsd:sequence>
<xsd:element name¼ ‘‘gene’’ type¼ ‘‘gene-
type’’ maxOccurs¼ ‘‘unbounded’’/>
</xsd:sequence>
</xsd:complexType>
<xsd:complexType name¼ ‘‘genetype’’>
<xsd:sequence>
<xsd:element name¼ ‘‘drug_interaction’’ type
¼ ‘‘DItype’’/>
</xsd:sequence>
<xsd:attribute name¼ ‘‘allele’’ type¼ ‘‘xsd:
string’’ use¼ ‘‘required’’/>
</xsd:complexType>
<xsd:complexType name¼ ‘‘DItype’’>
<xsd:sequence>
<xsd:element name¼ ‘‘inter_drug’’ type¼
‘‘xsd:string’’ minOccurs¼ ‘‘2’’ maxOccurs¼
‘‘2’’/>
<xsd:element name¼ ‘‘eﬀect_modiﬁcation’’
type¼ ‘‘xsd:string’’/>
</xsd:sequence>
</xsd:complexType>
</xsd:schema>
This schema states that we have a section of Patient
Variables. The element deﬁned is a ‘‘gene’’ element and
there could be others. The gene element has an attribute
indicating an allele. Under the gene element is a ‘‘drug
interaction’’ element, and there could be other elements
deﬁned. The ‘‘drug interaction’’ element contains a
comment that is the possible modiﬁcation of the drug
interaction due to the presence of the allele.Given this added information to the database, the
next time the adverse drug interaction program is run
for a patient receiving both lansoprazole and tacrolimus
the program could be enhanced to check the CYP ge-
nome information about the patient. If the information
exists, the presentation of the interaction could be
modiﬁed with the added text that relate to the text of the
drug interaction.
In the case study represented here, the patient’s ge-
nome was not checked with the polymerase chain reac-
tion analysis test until after the clinicians suspected a
problem with the CYP2C19 enzyme due to high con-
centrations of tacrolimus. For future patients, knowing
the genome before administration of both lansoprazole
and tacrolimus would help. Given that most of the time,
the CYP2C19 genome state is not known, the advice
from the database is to ‘‘monitor tacrolimus concen-
trations and clinical status.’’ However, if the CYP2C19
allele were known and were part of the patient record,
then that information with the added information in the
database could tailor the interaction output for the pa-
tient. The allele state could be known by a previous test,
or perhaps in the future, a patient’s genome could be
known and part of the patient’s record. Then the drug
interaction program would have the added task of
noting that the allele state of CYP2C19 aﬀects the in-
teractions and would check the patient’s genome before
continuing.7. Modiﬁcation of drug interaction program using the
database with genomic information
An example of an interactions report with genomic
information added to the program’s details is:
Interactions Report
March 05, 2004 (01:27 PM)
DRUG LIST IS
Lansoprazole
Tacrolimus
INTERACTION FOR:
Lansoprazole
Tacrolimus
Eﬀect 1:
Possible increased tacrolimus toxicity (mechanism
not established)
Reference citation:
M Homma et al., Eﬀects of lansoprazole and rabep-
razole on tacrolimus blood concentration: case of a
renal transplant recipient with CYP2C19 gene muta-
tion. Transplantation, 73:303, 2002;
MA Chisholm et al., Coadministration of tacrolimus
with anti-acid drugs. Transplantation, 76:665, 2003
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Single case report (2002) in patient with reduced
CYP2C19 activity; causal relationship not estab-
lished; monitor tacrolimus concentrations and clini-
cal status; neither rabeprazole nor famotidine
appeared to aﬀect tacrolimus; a small retrospective
study found no eﬀect of proton pump inhibitors on
tacrolimus, but few details were given [18].
Patient Speciﬁc Addition—Genomics data The patient
record indicates the presence of a CYP2C19*1/*2 al-
lele. Our genomics data for drug interactions sug-
gests: increased interaction risk, see interactions
comment and references.
Note: This patient speciﬁc addition was pasted from
the XML document to demonstrate adding informa-
tion based on genomic data.
It should be noted that the CYP2C19 enzyme is one
of many in the P450 enzyme system that aﬀect not only
drug interactions but drug administration in general.
Also, genomic information as part of the adverse drug
interaction database is one of many patient speciﬁc
variables that could be included in the database to make
it possible to give more patient speciﬁc output.8. Limitations and future of the current approach
This paper is meant to give an example of how ge-
nomic data could fairly easily be represented for use
with an existing product and database. This may lead to
new scientiﬁc methods, but that is an item for future
work. The current approach uses XML documents to
manage genomic, patient, and drug interaction infor-
mation. To do the necessary comparisons and relations
(e.g., comparing a patient’s genome from a patient re-
cord to the XML document of patient variables
<Patient_Variables> with genomic information) would
require transferring the XML document information to
a database system or using an application program in-
terface (API) so that program applications communicate
with an XML parser.
Future research would include investigations into
standardizing the allele information and the drug in-
teraction information, uploading the XML documents
to database systems, developing interfaces within an
electronic medical record (EMR), and the use of XML
parsers.9. Conclusion–summary
This paper used an established database of drug in-
teractions and searched for instances that might beneﬁt
from additional genomic information. It used anexample of Cytochrome P450 isoenzymes that partici-
pate in the metabolism of many drugs. There are genetic
variations in the metabolism of these drugs and this
paper shows how one could include diﬀerences in drug
interactions related to genetic diﬀerences as part of an
XML document. Furthermore, it suggests that with this
information in an XML document, with patient infor-
mation, and additional logic to a drug interaction pro-
gram, one could tailor the output of a drug interaction
program for the genetic speciﬁcs of the patient. The
result will be a decision support tool that utilizes phar-
macogenomic knowledge linked to patient data, which
will hopefully improve medication management, reduce
the incidence of adverse drug interactions, and reduce
toxicity in patients.References
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